DuoNeb Controversy
DuoNeb has been a subject of recent Medicare and U.S. Food and Drug Administration (FDA) controversy. FDA has moved for regulation of generic competition to commercial product whereas Medicare has moved to limit reimbursement of commercial product. Dispute resolution will have a material economic impact on leading respiratory service providers, as well as patients.
Read more about this topic: Ipratropium Bromide/salbutamol
Famous quotes containing the word controversy:
“And therefore, as when there is a controversy in an account, the parties must by their own accord, set up for right Reason, the Reason of some Arbitrator, or Judge, to whose sentence, they will both stand, or their controversy must either come to blows, or be undecided, for want of a right Reason constituted by Nature; so is it also in all debates of what kind soever.”
—Thomas Hobbes (1579–1688)